Seres Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Seres Therapeutics Inc MCRB.OQ reported a quarterly adjusted loss of 10 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -32 cents. The mean expectation of six analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -28 cents to -13 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Seres Therapeutics Inc's reported EPS for the quarter was a loss of 10 cents​.

• The company reported a quarterly loss of $15.64 million.

• Seres Therapeutics Inc shares had fallen by 16.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and 2 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Seres Therapeutics Inc is $1.25

This summary was machine generated from LSEG data March 13 at 08:55 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)